Teladoc Health, Inc. (NYSE:TDOC) Receives Consensus Recommendation of “Hold” from Brokerages

Teladoc Health, Inc. (NYSE:TDOC) has earned a consensus recommendation of “Hold” from the sixteen research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $7.5357.

A number of equities analysts recently commented on the company. Bank of America raised their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings raised Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Citigroup reduced their price target on Teladoc Health from $11.00 to $7.50 and set a “neutral” rating for the company in a research report on Monday. Finally, Canaccord Genuity Group decreased their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th.

Teladoc Health Trading Down 3.2%

Shares of TDOC stock opened at $6.71 on Friday. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.89. The stock has a market cap of $1.22 billion, a P/E ratio of -6.77 and a beta of 2.12. The company has a 50 day simple moving average of $8.21 and a two-hundred day simple moving average of $6.54.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The business had revenue of $606.93 million for the quarter, compared to analysts’ expectations of $615.44 million. During the same quarter last year, the company posted ($0.19) EPS. The company’s revenue was down 4.0% compared to the same quarter last year. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, equities analysts forecast that Teladoc Health will post -0.88 earnings per share for the current year.

Insider Activity

In other Teladoc Health news, insider Adam C. Vandervoort sold 7,906 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the sale, the insider owned 110,261 shares in the company, valued at approximately $841,291.43. This trade represents a 6.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Fernando M. Rodrigues sold 5,677 shares of Teladoc Health stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $43,315.51. Following the transaction, the insider directly owned 9,572 shares in the company, valued at $73,034.36. This represents a 37.23% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 39,195 shares of company stock valued at $299,058. 0.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new stake in Teladoc Health in the 2nd quarter worth $5,535,000. State of Wyoming purchased a new position in shares of Teladoc Health in the second quarter valued at about $532,000. Versant Capital Management Inc lifted its position in shares of Teladoc Health by 33.3% in the second quarter. Versant Capital Management Inc now owns 8,207 shares of the health services provider’s stock valued at $70,000 after acquiring an additional 2,052 shares in the last quarter. Essential Partners LLC bought a new position in shares of Teladoc Health in the first quarter worth about $113,000. Finally, Janus Henderson Group PLC boosted its stake in shares of Teladoc Health by 7.7% in the first quarter. Janus Henderson Group PLC now owns 262,215 shares of the health services provider’s stock worth $1,429,000 after acquiring an additional 18,679 shares during the period. Institutional investors own 76.82% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.